Newest Addition in Line with the Company’s Stated Goal of Expanding its Clinical and Scientific Teams as it Progresses Development and Ultimate Commercialization of its SEAL™ Device to Treat Brain Aneurysms MILPITAS, Calif. , June 18, 2025 /PRNewswire/ — Galaxy Therapeutics, a privately…
Financial
DESKi Closes $6M Seed Round to Bring AI-Powered Heart Scans to Market
BORDEAUX, France–(BUSINESS WIRE)–DESKi, a healthtech company developing AI-powered diagnostic tools in collaboration with clinicians and researchers, today announced the close of a $6 million seed round to support the U.S. and global market launch of its FDA-approved cardiac imaging software, HeartFocus. “This funding moves us one step closer to a world […]
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Verve’s leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly’s established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve’s vision and…
Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt
Existing investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from…
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 LockeT sales are already outpacing Q2 2024 sales with a 200% increase.
Anaconda Biomed Appoints Dr. Charles Carignan as New Chairman of the Board of Directors
BARCELONA, Spain & MARIN, Calif.–(BUSINESS WIRE)–Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, announced today the appointment of long-time medtech executive Charles (Chuck) Carignan, M.D., as chairman of the board. Dr. Carignan is joining the company at a critical time as enrollment […]
Koya Medical Opens New Dallas HQ to Power Next Phase of Growth in Vascular Health
DALLAS, June 10, 2025 /PRNewswire/ — Koya Medical (“Koya”), a global leader in vascular health innovation, today announced the grand opening of its new 35,000-square-foot headquarters in Dallas, Texas. This state-of-the-art facility becomes the new nerve center for Koya’s manufacturing…
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch execution The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch execution
PaceMate® Names JR Finkelmeier CEO As It Sets Its Sights on Large-Scale Expansion
Founding CEO Tripp Higgins To Become Chairman of the Board of Directors, Supporting the Leadership Transition As Finkelmeier Puts Operational Structure in Place to Meet Growing Demand SARASOTA, Fla.–(BUSINESS WIRE)–PaceMate, the cardiac remote monitoring platform that leading healthcare providers trust, today announced the appointment of JR Finkelmeier as Chief Executive […]
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap® Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution when the U.S. market opens on Monday, June 30, 2025.



